It was a pleasure to talk with Prof. Nicolas Girard (Institut Curie; Versailles Saint Quentin University, Paris, France) to discuss the findings from his analysis of event-free survival in the CheckMate-816 trial, investigating neoadjuvant nivolumab plus chemotherapy for resectable (IB-IIIA) non-small cell lung cancer.
The abstract ‘Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer (NSCLC): Event-free survival (EFS) results from the phase 3 CheckMate 816 trial.’ (Abstract number CT012) was presented at AACR 2022, 8-13 April, 2022.
Questions
- What was the rationale for the use of an immunotherapy-based combination treatment in non-small cell lung cancer (NSCLC)? (0:13)
- What were the aims and design of the CheckMate-816 study investigating neoadjuvant nivolumab (NIVO) plus chemotherapy (CHEMO) in NSCLC? (1:20)
- What was the rationale for your analysis of event-free survival in the CheckMate-816 trial? (2:37)
- What were the findings from your analysis? (3:44)
- What do these findings mean for clinical practice and what further studies are needed? (5:07)
Disclosures: Nicolas Girard has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the AACR annual meeting 2022.
